VNDA Vanda Pharmaceuticals Inc. Stock Quote

VNDA [NASD]

Index	-	P/E	44.19	EPS (ttm)	0.42	Insider Own	2.60%	Shs Outstand	54.73M	Perf Week	-0.27%
Market Cap	1.06B	Forward P/E	23.70	EPS next Y	0.79	Insider Trans	-9.74%	Shs Float	53.10M	Perf Month	29.60%
Income	23.30M	PEG	-	EPS next Q	0.10	Inst Own	-	Short Float	10.70%	Perf Quarter	51.13%
Sales	248.20M	P/S	4.28	EPS this Y	-79.90%	Inst Trans	1.87%	Short Ratio	10.05	Perf Half Y	79.33%
Book/sh	8.28	P/B	2.25	EPS next Y	54.01%	ROA	4.60%	Target Price	21.00	Perf Year	69.55%
Cash/sh	6.46	P/C	2.89	EPS next 5Y	-	ROE	5.40%	52W Range	7.12 - 20.51	Perf YTD	41.93%
Dividend	-	P/FCF	21.24	EPS past 5Y	19.60%	ROI	4.20%	52W High	-9.07%	Beta	0.54
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	17.70%	Gross Margin	90.60%	52W Low	161.94%	ATR	1.03
Employees	292	Current Ratio	6.20	Sales Q/Q	11.20%	Oper. Margin	11.00%	RSI (14)	62.81	Volatility	5.83% 6.59%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	92.10%	Profit Margin	9.40%	Rel Volume	0.88	Prev Close	19.35
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 10 AMC	Payout	0.00%	Avg Volume	565.29K	Price	18.65
Recom	2.00	SMA20	10.72%	SMA50	24.50%	SMA200	53.66%	Volume	501,427	Change	-3.62%

Jan-14-21

Downgrade

Citigroup

Buy → Neutral

$14

Oct-29-20

Upgrade

Citigroup

Neutral → Buy

$14

Jun-09-20

Downgrade

Citigroup

Buy → Neutral

$14

Mar-16-20

Downgrade

Oppenheimer

Perform → Underperform

Mar-12-20

Upgrade

Citigroup

Neutral → Buy

$14

Nov-07-19

Downgrade

Citigroup

Buy → Neutral

$19

Aug-01-19

Upgrade

Citigroup

Neutral → Buy

$19

Jul-25-19

Downgrade

Stifel

Buy → Hold

$26 → $17

Dec-11-18

Downgrade

Oppenheimer

Outperform → Perform

Dec-04-18

Upgrade

Cantor Fitzgerald

Neutral → Overweight

Dec-04-18

Reiterated

Jefferies

Buy

$30 → $40

Nov-08-18

Resumed

Jefferies

Buy

Sep-21-18

Resumed

Oppenheimer

Outperform

May-23-18

Initiated

Citigroup

Buy

$26

Jan-19-18

Initiated

Seaport Global Securities

Buy

$20

Sep-14-17

Reiterated

Piper Jaffray

Overweight

$23 → $26

Jun-27-17

Resumed

Piper Jaffray

Overweight

$23

May-26-17

Initiated

H.C. Wainwright

Buy

$18

Apr-12-17

Initiated

Oppenheimer

Outperform

$21

Nov-09-16

Initiated

Aegis Capital

Buy

$24

Feb-23-21 02:49PM	Pacira Pharmaceuticals Getting Closer To Key Technical Measure Investor's Business Daily
Feb-14-21 01:32PM	15 Best Small-Cap Healthcare Stocks to Buy Insider Monkey
Feb-12-21 12:54AM	Vanda Pharmaceuticals Inc. Just Missed Earnings - But Analysts Have Updated Their Models Simply Wall St.
Feb-11-21 10:28AM	Return On Capital Employed Overview: Vanda Pharmaceuticals Benzinga +21.16%
Feb-10-21 08:30PM	Vanda Pharmaceuticals Inc (VNDA) Q4 2020 Earnings Call Transcript Motley Fool
04:28PM	Recap: Vanda Pharmaceuticals Q4 Earnings Benzinga
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire
07:34AM	The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga
Feb-02-21 04:30PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021 PR Newswire
Dec-19-20 06:11PM	Is VNDA A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-02-20 03:02PM	Here's Why Vanda Pharmaceuticals Jumped Higher Today Motley Fool +9.32%
07:35AM	The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga
Dec-01-20 06:00PM	FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome PR Newswire
04:47AM	Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Is Going Strong: Have Financials A Role To Play? Simply Wall St.
Nov-17-20 12:43PM	Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed Zacks
Oct-29-20 09:31AM	Benzinga's Top Upgrades, Downgrades For October 29, 2020 Benzinga +8.97%
Oct-28-20 05:55PM	Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates Zacks
04:01PM	Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire
02:30PM	Vanda Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-26-20 04:01PM	Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis PR Newswire
Oct-21-20 04:45PM	Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020 PR Newswire
Oct-13-20 01:14PM	Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Oct-02-20 01:44PM	How Does Vanda Pharmaceuticals' (NASDAQ:VNDA) CEO Pay Compare With Company Performance? Simply Wall St.
Sep-15-20 03:41PM	Top Biotech Stocks for Q4 2020 Investopedia
Aug-31-20 06:30PM	Vanda Pharmaceuticals Provides Update on Tradipitant Development Program PR Newswire
Aug-18-20 10:24AM	Would Shareholders Who Purchased Vanda Pharmaceuticals'(NASDAQ:VNDA) Stock Three Years Be Happy With The Share price Today? Simply Wall St. -8.20%
07:00AM	Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia PR Newswire
Aug-06-20 08:21PM	Oil Down But OPEC+ Member Cuts Cap Losses Investing.com
Aug-05-20 06:05PM	Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates Zacks
04:01PM	Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results PR Newswire
Aug-03-20 08:53AM	Were Hedge Funds Right About Vanda Pharmaceuticals Inc. (VNDA)? Insider Monkey
07:00AM	FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome PR Newswire
Jul-29-20 05:00PM	Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020 PR Newswire
Jul-22-20 12:32PM	Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-21-20 04:04PM	Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA) Business Wire
Jul-14-20 11:02AM	FDA Grants Extra Access to Vanda's Tradipitant to a Patient Zacks
08:04AM	The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits Benzinga
Jul-13-20 04:30PM	FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis PR Newswire
Jun-19-20 02:38PM	Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Sticking Around Insider Monkey
May-26-20 07:00AM	Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting PR Newswire
May-21-20 05:08PM	U.S. doctors call for remdesivir data to guide coronavirus treatment Reuters
May-20-20 05:20PM	Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit PR Newswire +6.73%
10:45AM	Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir PR Newswire
May-15-20 11:43AM	1 Pharma Stock to Avoid at All Costs Motley Fool
May-14-20 07:03AM	This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19 Motley Fool
May-13-20 07:00AM	Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome PR Newswire
May-08-20 07:32PM	Edited Transcript of VNDA earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-07-20 11:31AM	Vanda Pharmaceuticals (VNDA) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 06:45PM	Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates Zacks
Apr-29-20 04:05PM	Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
12:34PM	Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-27-20 02:18PM	What Is Vanda Pharmaceuticals's (NASDAQ:VNDA) P/E Ratio After Its Share Price Rocketed? Simply Wall St.
Apr-23-20 09:12AM	Another 140,000 apply for unemployment benefits in D.C., Md. and Va. American City Business Journals
Apr-22-20 01:01PM	Is Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Paid At A Competitive Rate? Simply Wall St.
Apr-21-20 05:14PM	This company gets FDA green light to proceed with study on possible COVID-19 treatment Yahoo Finance Video
Apr-17-20 10:00AM	Company News for Apr 17, 2020 Zacks
08:54AM	Northam requests more federal aid, Montgomery County steps up PPE funding American City Business Journals
Apr-16-20 10:58AM	Vanda Begins Enrollment in Study for Severe Coronavirus Infection Zacks +6.91%
08:09AM	The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant Benzinga
Apr-15-20 04:15PM	Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine PR Newswire -7.79%
04:05PM	Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia PR Newswire
Apr-09-20 07:52AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall Benzinga
Apr-08-20 04:05PM	Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19 PR Newswire
Apr-03-20 02:26PM	These D.C.-area biotech companies are making progress on COVID-19. Heres the latest. American City Business Journals -6.81%
Apr-02-20 01:36PM	Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia PR Newswire +14.08%
Mar-19-20 12:59PM	Vanda Pharmaceuticals hits another snag with FDA American City Business Journals +9.47%
Mar-10-20 05:13PM	Edited Transcript of VNDA earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +8.69%
Feb-27-20 05:35PM	Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences PR Newswire
Feb-26-20 03:05PM	Vandas latest study failed. But revenue grew in 2019. American City Business Journals
Feb-25-20 04:13PM	Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis PR Newswire
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results PR Newswire
Feb-21-20 12:26PM	Should We Be Delighted With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) ROE Of 30%? Simply Wall St. -9.13%
Feb-19-20 07:00AM	Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors PR Newswire
Feb-18-20 08:22PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 PR Newswire +5.28%
Feb-05-20 09:15AM	Vertex (VRTX) Hits 52-Week High, Can the Run Continue? Zacks
Feb-03-20 03:28PM	Court rules against Vanda, in favor of FDA on clinical trials suit American City Business Journals
Jan-31-20 06:24PM	Vanda Pharmaceuticals Comments on Court Ruling PR Newswire
Jan-16-20 02:57PM	Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat. American City Business Journals
Jan-13-20 02:11PM	Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt® PR Newswire -5.61%
Jan-12-20 03:34PM	3 Small Caps to Consider for Growth GuruFocus.com
Dec-29-19 09:40PM	Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-23-19 02:27PM	Do Vanda Pharmaceuticals's (NASDAQ:VNDA) Earnings Warrant Your Attention? Simply Wall St.
Dec-12-19 05:15PM	Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award PR Newswire
Dec-10-19 09:12PM	Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds In Wait-and-See Mode Insider Monkey
Nov-19-19 07:15AM	Edited Transcript of VNDA earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 04:01PM	Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences PR Newswire
10:04AM	These Stocks Could Bounce High in January and Beyond GuruFocus.com
Nov-14-19 10:35AM	Top Ranked Value Stocks to Buy for November 14th Zacks
Nov-07-19 07:18AM	The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga +10.58%
Nov-06-19 04:01PM	Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results PR Newswire
Oct-31-19 01:25PM	Hedge Funds Have Never Been Less Bullish On Vanda Pharmaceuticals Inc. (VNDA) Insider Monkey
Oct-30-19 04:30PM	Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019 PR Newswire
10:33AM	Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 04:30PM	Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors PR Newswire
Oct-23-19 04:01PM	Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs PR Newswire
Oct-16-19 04:01PM	Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement PR Newswire
Oct-15-19 08:25AM	SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces that Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors; Shareholders Urged to Contact the Firm ACCESSWIRE
Oct-10-19 01:49PM	Volatility 101: Should Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Have Dropped 42%? Simply Wall St.
Sep-25-19 06:18PM	Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study Zacks +5.53%
Sep-11-19 05:20PM	Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies PR Newswire

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Aranthan II	Chief Corp. Affairs Officer	Feb 24	Option Exercise	12.27	22,499	276,063	123,786	Feb 26 05:17 PM
Jones Aranthan II	Chief Corp. Affairs Officer	Feb 24	Sale	20.01	22,986	460,033	100,800	Feb 26 05:17 PM
Watkins Thomas	Director	Feb 16	Option Exercise	7.11	15,000	106,650	55,323	Feb 18 08:43 PM
DUGAN RICHARD W	Director	Feb 16	Option Exercise	7.11	15,000	106,650	60,641	Feb 18 08:43 PM
Watkins Thomas	Director	Feb 16	Sale	18.54	5,818	107,856	49,505	Feb 18 08:43 PM
DUGAN RICHARD W	Director	Feb 16	Sale	18.54	5,754	106,663	54,887	Feb 18 08:43 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 15	Option Exercise	8.75	46,663	408,301	1,342,897	Dec 15 04:24 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 15	Sale	13.00	39,150	508,844	1,303,747	Dec 15 04:24 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 14	Option Exercise	8.75	61,520	538,300	1,347,283	Dec 15 04:24 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 14	Sale	13.19	51,049	673,306	1,296,234	Dec 15 04:24 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 11	Option Exercise	8.75	41,817	365,899	1,320,816	Dec 15 04:24 PM
Polymeropoulos Mihael Hristos	President and CEO	Dec 11	Sale	12.88	35,053	451,360	1,285,763	Dec 15 04:24 PM
Wijkstrom Joakim	SVP, Chief Marketing Officer	Aug 20	Sale	11.08	3,710	41,109	56,290	Aug 21 06:08 PM
Williams Timothy	SVP & General Counsel	Aug 14	Sale	11.81	3,684	43,526	79,356	Aug 17 04:42 PM
Jones Aranthan II	Chief Corp. Affairs Officer	Aug 12	Sale	11.81	7,200	85,018	75,487	Aug 14 04:39 PM
Jones Aranthan II	Chief Corp. Affairs Officer	Jul 27	Sale	10.62	7,313	77,631	82,687	Jul 29 08:17 PM
Watkins Thomas	Director	May 29	Option Exercise	7.38	15,000	110,700	45,000	Jun 02 04:13 PM
Watkins Thomas	Director	May 29	Sale	11.50	9,677	111,286	35,323	Jun 02 04:13 PM
DUGAN RICHARD W	Director	May 28	Option Exercise	7.38	15,000	110,700	50,770	May 29 04:10 PM
DUGAN RICHARD W	Director	May 28	Sale	11.04	10,129	111,806	40,641	May 29 04:10 PM
Kelly James Patrick	EVP & Chief Financial Officer	Mar 03	Sale	10.76	5,889	63,359	186,869	Mar 04 05:01 PM
Birznieks Gunther	SVP, Business Development	Mar 03	Sale	10.66	5,535	58,984	159,473	Mar 04 05:00 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 03	Sale	10.98	5,152	56,544	1,278,999	Mar 04 05:02 PM
Williams Timothy	SVP & General Counsel	Mar 03	Sale	10.51	1,237	13,004	83,040	Mar 04 05:03 PM
Reverberi Gian Piero	SVP & Chief Commercial Officer	Mar 02	Sale	10.18	1,450	14,755	165,384	Mar 04 05:02 PM
Williams Timothy	SVP & General Counsel	Mar 02	Sale	10.30	3,148	32,436	84,277	Mar 04 05:03 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 02	Sale	10.57	10,428	110,211	1,284,151	Mar 04 05:02 PM
Birznieks Gunther	SVP, Business Development	Mar 02	Sale	10.04	12,223	122,686	165,008	Mar 04 05:00 PM
Kelly James Patrick	EVP & Chief Financial Officer	Mar 02	Sale	10.19	12,968	132,087	192,758	Mar 04 05:01 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience